DDInter1141 DDInter233
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Difluprednate
Difluprednate {u} (Compound) resembles {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Brigatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Megestrol acetate (Compound) resembles Difluprednate (Compound) and Difluprednate (Compound) resembles Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Brigatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib